Pomerantz Law Firm Issues Alert on Zenas BioPharma Class Action Lawsuit and Deadlines

Pomerantz Law Firm Alerts Investors on Zenas BioPharma Class Action

The Pomerantz Law Firm has publicly announced a class action lawsuit against Zenas BioPharma, Inc., a company listed under NASDAQ as ZBIO. Investors who have experienced financial losses from their investments in Zenas are encouraged to take immediate action. The law firm reminds affected individuals to reach out for support before the upcoming deadline of June 16, 2025, to secure their rights as potential class members in the lawsuit.

The class action lawsuit centers around allegations that Zenas and its executives may have engaged in fraudulent securities practices. This comes in light of the company's recent initial public offering (IPO), which was executed on or around September 13, 2024. During this IPO, Zenas offered approximately 13.235 million shares at a price of $17.00 each. However, troubling news surfaced when Zenas released its quarterly report on November 12, 2024, where it indicated that the company could fund its operations for only the next twelve months—a much shorter window than previously stated in its IPO registration documents, which had forecasted funding for twenty-four months.

This significant update has led to a steep decline in Zenas's stock price, thus negatively impacting investors who trusted the company's financial stability as projected during the IPO. Those who purchased or obtained Zenas securities in regard to or following its IPO are specifically encouraged to seek representation and may request to be appointed as Lead Plaintiff in the class-action context if they act swiftly.

Pomerantz LLP, recognized as a leading firm in the realm of corporate, securities, and antitrust class litigation, remains dedicated to fighting for the rights of investors. The firm was founded by the late Abraham L. Pomerantz, widely regarded as a trailblazer in securities class actions, and it has maintained its esteemed reputation for over 85 years. To date, the firm has successfully recovered numerous multi-million dollar settlements for class members affected by breaches of fiduciary duty or corporate misconduct.

Investors who are affected by this situation are strongly encouraged to contact Danielle Peyton at the Pomerantz Law Firm through the provided channels. Individuals are invited to include pertinent information such as their mailing address, phone number, and specifics regarding their stock purchases in their inquiries, which can assist in expediting the process of joining the class action.

For further details about the class action lawsuit, including access to the formal complaint, interested parties can visit the Pomerantz website. Engaging early in the process is imperative for those who wish to hold Zenas accountable for potential misrepresentation and inadequate disclosure regarding its financial position.

In closing, affected individuals should weigh their options carefully and consider involvement in this class action, especially given the legal precedent set by Pomerantz LLP in recovering losses for investors in similar situations. The stakes are high, and timely action may be crucial for those with claims against Zenas BioPharma.

For inquiries, reach out to: